| Combination of fatty acid synthase (FASN) inhibitor and thyroid hormone receptor beta (THRb) agonist resmetirom shows synergistic improvement of NAFLD activity score (NAS) within 6-weeks in diet-induced obese mice with biopsy-confirmed MASH | EASL International Liver Congress
| poster | 06/2024 |
| Combination of fatty acid synthase (FASN) inhibitor and thyroid hormone receptor beta (THRb) agonist, resmetirom, improved markers of MASH and cardiovascular health in LDL receptor knockout MASH mice | EASL International Liver Congress
| poster | 06/2024 |
| Denifanstat, a fatty acid synthase (FASN) inhibitor, shows significant fibrosis improvement and MASH resolution in FASCINATE-2, a Ph2b 52 week global, randomized, double blind, placebo-controlled trial in patients with F2 or F3 fibrosis | EASL International Liver Congress
| oral | 06/2024 |
| Evaluation of FASN inhibitor & GLP-1 Combination in Preclinical Mouse Model | 7th Obesity and NASH Drug Development Summit
| oral | 11/2023 |
| Artificial Intelligence Based Digital Pathology Reveals Fatty Acid Synthase (FASN) Inhibitor Alone or in Combination with Semaglutide Improves Fibrosis in Diet-Induced Obese Mice with Biopsy-Confirmed NASH and Fibrosis | AASLD The Liver Meeting
| poster | 11/2023 |
| Interim Analysis of FASCINATE-2 A Phase 2b Randomized, Placebo Controlled Trial Demonstrated Denifanstat Reduces Circulating Saturated Diacylglycerols and Triacylglycerols, Markers of Lipotoxicity | AASLD The Liver Meeting
| late-breaking poster | 11/2023 |
| Denifanstat, a fatty acid synthase (FASN) inhibitor for the treatment of biopsy-proven NASH: A 26-week interim analysis of the FASCINATE-2 Phase 2b trial | EASL International Liver Congress
| oral | 06/2023 |
| Phase II Investigation of TVB-2640 (denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma | Clinical Cancer Research
| paper | 04/2023 |
| Combination of fatty acid synthase inhibitor with tyrosine kinase inhibitors shows synergistic efficacy in HCC preclinical models, a novel potential approach for clinical development | HCC-TAG
| poster | 02/2023 |
| Denifanstat (DEN), a first-in-class fatty acid synthase (FASN) inhibitor, significantly reduces plasma tripalmitin, a marker of de novo lipogenesis, in NASH patients in the FASCINATE-1 and FASCINATE-2 clinical studies | NASH-TAG
| poster | 01/2023 |
| Serum metabolomic, lipidomic and proteomic profiling identifies new biomarkers associated with the treatment of denifanstat, a fatty acid synthase inhibitor, in NASH patients | NASH-TAG
| poster | 01/2023 |
| Correlation between AI-based digital pathology and non-invasive tests (NITs) – baseline data from the FASCINATE-2 phase 2b clinical study of denifanstat in patients with F2/F3 NASH | AASLD The Liver Meeting
| oral | 11/2022 |
| A baseline metabolomic signature predicts liver fat (MRI-PDFF) response for denifanstat, a first-in-class, fatty acid synthase (FASN) inhibitor: analysis in FASCINATE-1 and FASCINATE-2 clinical studies | AASLD The Liver Meeting
| poster | 11/2022 |
| Serum proteomic profiling reveals that the fatty acid synthase (FASN) inhibitor denifanstat provides metabolic benefits via increasing fibroblast growth factor 19 (FGF19) and decreasing 3-hydroxy-3-methylglutaryl-coa synthase 1 (HMGCS1) in NASH patients | AASLD The Liver Meeting
| poster | 11/2022 |
| FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models | Scientific Reports
| paper | 09/2022 |
| Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer | Nature Communications
| paper | 07/2022 |
| A baseline signature of metabolites involving the gut-liver axis predicts MRI-PDFF response to FASN inhibitor TVB-2640 in NASH patients: results from the FASCINATE-1 study | EASL International Liver Congress
| poster | 06/2022 |
| Novel, first-in-class, fatty acid synthase (FASN) inhibitor TVB-2640: efficacy, safety and biomarker results from a global phase 2 randomized pbo-controlled NASH trial, FASCINATE-1 | Digestive Disease Week
| poster | 05/2022 |
| Novel, first-in-class, fatty acid synthase (FASN) inhibitor TVB-2640 demonstrates robust clinical efficacy and safety in a global phase 2 randomized placebo-controlled NASH trial (FASCINATE-1) | NASH-TAG
| poster | 01/2022 |
| Therapeutic efficacy of FASN inhibition in preclinical models of HCC | Hepatology
| paper | 01/2022 |
| TVB-2640, a novel, first-in-class, fatty acid synthase (FASN) inhibitor: biomarker and metabolomic correlations with clinical MRI-PDFF response | NASH Summit
| oral | 11/2021 |
| Novel, first-in-class, fatty acid synthase (FASN) inhibitor TVB-2640 demonstrates robust clinical efficacy and safety in a global phase 2 randomized placebo-controlled NASH trial (FASCINATE-1) conducted in the U.S. and China | AASLD The Liver Meeting
| oral | 11/2021 |
| Translation of FASN Inhibitor TVB-2640 from Preclinical MOA to Clinical POC in NASH | NASH and Fibrosis Conference
| oral | 09/2021 |
| TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial | Gastroenterology
| paper | 07/2021 |
| Analysis of non-invasive biomarker tests in the Phase 2 FASCINATE-1 study of FASN inhibitor TVB-2640 | EASL International Liver Congress
| poster | 06/2021 |
| First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors | EClinicalMedicine
| paper | 04/2021 |
| Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH | AASLD
| oral | 11/2020 |
| TVB-2640 with Bevacizumab in Relapsed High-grade Astrocytoma | European Society for Medical Oncology (ESMO) Congress
| oral | 09/2020 |
| Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH | EASL International Liver Congress
| oral | 08/2020 |
| The FASN inhibitor TVB-2640 is efficacious in a new 3D human liver microtissue model of NASH | EASL International Liver Congress
| poster | 08/2020 |
| Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities | Hepatology 2020
| paper | 07/2020 |
| FASN inhibitor TVB-2640 in NASH | NASH-TAG
| oral | 01/2020 |
| Updated Results from a Prospective Phase 2 Study in Patients with First Relapse of High-grade Astrocytoma Using TVB-2640 in Combination with bevacizumab | ASCO
| poster | 06/2019 |
| FASN inhibition as a potential treatment for therapy of endocrine resistant breast cancer | San Antonio Breast Cancer Symposium
| poster | 12/2018 |
| Fibroblast Growth Factor-21 and its Relationship to Human Liver Fat Synthesis; Impact of a New Therapeutic Agent | ObesityWeek
| poster | 11/2018 |
| The FASN inhibitor, TVB3664, Ameliorates NASH in a Murine Model | AASLD
| poster | 11/2018 |
| Updated results from a prospective, randomized phase 2 study in patients with first relapse of high-grade astrocytoma using TVB-2640 in combination with Avastin versus Avastin alone | Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
| poster | 11/2018 |
| Progressive Reductions in Hepatic DNL with Increasing Doses of TVB-2640, a First-in-Class Pharmacologic Inhibitor of FASN | Keystone Symposium on Organ Crosstalk in Obesity and NAFLD
| poster | 01/2018 |
| Fatty acid synthase inhibitor TVB-3664 reverses multiple components of diet-induced nonalcoholic steatohepatitis in mice treated with or without co-administered pirfenidone and reduces collagen accumulation in bleomycin-induced murine skin fibrosis | AASLD
| poster | 10/2017 |
| Pharmacologic Inhibition of FASN Reverses Diet-Induced Steatohepatitis in Mice and Inhibits Lipogenesis in Humans. | AASLD
| poster | 10/2017 |
| First in human study of the first-in-class fatty acid synthase (FASN) inhibitor TVB-2640 | AACR Annual Meeting
| oral | 04/2017 |
| Establishing the foundation for a novel, first-in-class, fatty acid synthase inhibitor, TVB-2640, for the treatment of NASH | EASL International Liver Congress
| poster | 04/2017 |
| Fatty Acid Synthase – Modern Tumor Cell Biology Insights into a Classical Oncology Target | Pharmacology and Therapeutics
| paper | 02/2017 |
| Heavily Pre-Treated Breast Cancer Patients show Promising Responses in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 in Combination with Paclitaxel | San Antonio Breast Cancer Symposium
| poster | 12/2016 |
| FASN inhibition and taxane treatment combine to enhance anti-tumor efficacy in diverse xenograft tumor models through disruption of tubulin palmitoylation and microtubule organization and FASN inhibition-mediated effects on oncogenic signaling and gene expression | EBioMedicine
| paper | 12/2016 |
| Pharmacological inhibition of FASN Prevents High Fat Diet Induced Liver Damage in Mice and Significantly Reduces de novo Lipogenesis in Humans | AASLD The Liver Meeting
| poster | 11/2016 |
| Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase Inhibitor, TVB-2640 | NCRI Cancer Conference
| poster | 11/2016 |
| Mechanism and rationale for inhibition of FASN as a novel therapy for KRAS-mutant non-small cell lung cancer patients | Precison: Lung Cancer R&D Summit
| oral | 09/2016 |
| DeNovo Palmitate Synthesis Supports Oncogenic Signaling Through Diverse Mechanisms: Implications for FASN-Targeted Therapeutics | Journal of Cell Signaling
| paper | 08/2016 |
| Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 | ASCO Annual Meeting
| poster | 06/2016 |
| FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS mutant NSCLC patients in a Phase 1 study | AACR Annual Meeting
| poster | 04/2016 |
| Preclinical studies characterize tumor type sensitivity to FASN inhibition and the mechanism and efficacy of novel drug combinations with TVB-2640 | AACR Annual Meeting
| poster | 04/2016 |
| Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 | International Congress on Targeted Anticancer Therapies
| oral | 03/2016 |
| Sebum Analysis from Dose Escalation and Expansion Phases of the FASN Inhibitor TVB-2640 Phase 1 Trial, A Non-Invasive Biomarker of Target Engagement | Keystone Symposium – New Frontiers in Understanding Tumor Metabolism
| poster | 02/2016 |
| Sebum Analysis from Dose Escalation and Expansion Phases of the FASN Inhibitor TVB-2640 Phase 1 Trial, A Non-Invasive Biomarker of Target Engagement | Keystone Symposium – New Frontiers in Understanding Tumor Metabolism
| oral | 02/2016 |
| Direct Inhibition of Cellular Fatty Acid Synthase Impairs Replication of Respiratory Synctial Virus and Other Respiratory Viruses | PLOS ONE
| paper | 12/2015 |
| A First in Human Study of the First in Class Fatty Acid Synthase (FASN) Inhibitor TVB-2640. Results of Dose Escalation in Mono and Combination and Evidence of Preliminary Activity | EORTC-NCI-AACR International Conference
| poster | 11/2015 |
| Biomarker Analyses from Dose Escalation and Expansion Phases of FASN Inhibitor TVB-2640 Phase 1 Study Shows Target Engagement in Solid Tumor Patients | EORTC-NCI-AACR International Conference
| poster | 11/2015 |
| FASN inhibition studies in preclinical tumor models identify biomarkers that align with in vitro and in vivo sensitivity to TVB-2640 | EORTC-NCI-AACR International Conference
| poster | 11/2015 |
| Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression | EBioMedicine
| paper | 07/2015 |
| Translational Studies of a First-in-class FASN Inhibitor, TVB-2640, Linking Preclinical Studies to Clinical Laboratory Observations in Solid Tumor Patients | AACR Special Conference: Metabolism and Cancer
| poster | 06/2015 |
| First-in-Human Investigation of the Oral First-in-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 | ASCO Annual Meeting
| poster | 06/2015 |
| Diacylglycerol Metabolism and Signaling Is a Driving Force Underlying FASN Inhibitor Sensitivity in Cancer Cells | ACS Chemical Biology
| paper | 04/2015 |
| Discovery of tumor types highly susceptible to FASN inhibition and biomarker candidates for clinical analysis | AACR Annual Meeting
| poster | 04/2015 |
| Biomarker and PK/PD analyses of first-in-class FASN inhibitor TVB-2640 in a first-in-human phase 1 study in solid tumor patients | AACR Annual Meeting
| poster | 04/2015 |
| Report of a First-In-Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 | AACR Annual Meeting
| poster | 04/2015 |
| Initial report of a first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640 | EORTC-NCI-AACR International Conference
| oral | 11/2014 |
| Mechanistic analysis of reversible FASN inhibition in preclinical tumor models identifies highly susceptible tumor types and enriches biomarker discovery for clinical applications | EORTC-NCI-AACR International Conference
| poster | 11/2014 |
| Efficacy of FASN-selective small molecule inhibitors of preclinical tumor models | AACR Annual Meeting
| poster | 04/2014 |
| Inhibition of Fatty Acid Synthase in vitro and in vivo Reduces RSV Replication | Keystone Meeting – Pathogenesis of Respiratory Viruses
| poster | 01/2014 |
| Characterization of small-molecule FASN inhibitors in preclinical tumor models | AACR-NCI-EORTC International Conference
| poster | 10/2013 |
| Imidazopyridine-Based Fatty Acid Syhthase Inhibitors That Show Anti-HCV Activity and in Vivo Target Modulation | ACS Medicinal Chemistry Letters
| paper | 12/2012 |
| Potent HCV Antiviral Activity by Inhibiting Fatty Acid Synthase | AASLD The Liver Meeting
| oral | 11/2012 |
| A Novel, Host-Directed Small Molecule Inhibitor of HCV Displays Sustained Pharmacological Inhibition of Liver Fatty Acid Synthase | AASLD The Liver Meeting
| poster | 11/2012 |
